Madrigal Pharmaceuticals (NASDAQ:MDGL) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 22, MDGL announced a $500 million senior secured credit facility with Blue Owl Capital Inc. (NYSE:OWL), including a $350 million initial term loan and a $150 million delayed draw option through 2027.
A doctor wearing a lab coat in a research laboratory, holding up a flask of a potential biotechnology therapeutic solution.
The non-dilutive funding will refinance $115 million in existing debt and support strategic growth, with potential for an additional $250 million. Madrigal maintains a strong current ratio of 5.91, signaling solid liquidity.
The capital will primarily advance Madrigal’s pipeline for metabolic dysfunction-associated steatohepatitis (MASH), led by its FDA-approved drug Rezdiffra—the first treatment for MASH with moderate to advanced fibrosis. A Phase 3 trial is underway to evaluate Rezdiffra for compensated MASH cirrhosis. With strong launch momentum and a patent expected to extend protection through 2044, Madrigal is positioned to lead in MASH therapeutics.
Madrigal Pharmaceuticals is a biotech company that develops and commercializes novel therapies for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH).
READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks.
This article is originally published at Insider Monkey.
